通过人工智能,无细胞合成和冷EM,Nuclera和leadXpro合作加速对坚固膜蛋白的药物发现. Nuclera and leadXpro partner to accelerate drug discovery for tough membrane proteins using AI, cell-free synthesis, and cryo-EM.

核子和leadXpro已经建立了合作伙伴关系,以加快针对具有挑战性的膜蛋白的药物发现,使用无细胞蛋白合成,人工智能驱动的设计和冷EM分析的联合方法. Nuclera and leadXpro have formed a partnership to speed up drug discovery targeting challenging membrane proteins, using a combined approach of cell-free protein synthesis, AI-driven design, and cryo-EM analysis. 合作将快速实验筛查与迭代AI反馈相结合,以提高蛋白质稳定性、产量和结构准确性,减少发展时间和风险。 The collaboration integrates rapid experimental screening with iterative AI feedback to improve protein stability, yield, and structural accuracy, reducing development time and risk. 目标是克服在研究这些关键药物目标方面长期存在的瓶颈,加速治疗发展。 The goal is to overcome longstanding bottlenecks in studying these critical drug targets and accelerate therapeutic development.